Pacific Biosciences of Californ
PACB
Positions held
Your positionsPACB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $714.91M | Enterprise value | $1.19B | Trailing P/E | — | Forward P/E | -5.46 |
| PEG | — | Price / book | -21.50 | Beta | 2.19 | Dividend yield | 0.00% |
| Revenue growth | -1.9% | Earnings growth | — | Gross margin | 29.4% | Operating margin | -114.4% |
| Profit margin | -82.5% | ROE | -9.3% | ROA | -14.1% | Debt / equity | — |
| Current ratio | 4.92 | Free cash flow | $291.64M | Analyst recommendation | buy | Mean target | $2.40 |
| 52w high | $3.44 | 52w low | $1.07 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $39.0M | $37.2M | $44.6M | $38.4M | $39.8M | — |
| Op margin | -114.4% | -145.7% | -92.3% | -101.1% | -112.8% | — |
| Net income | -$44.7M | -$8.3M | -$40.4M | -$38.0M | -$41.9M | — |
| Gross margin | 32.4% | 34.5% | 37.1% | 41.4% | 36.9% | — |
| Gross profit | $12.6M | $12.8M | $16.6M | $15.9M | $14.7M | — |
| Operating income | -$44.6M | -$54.2M | -$41.2M | -$38.9M | -$44.9M | — |
- Revenue +5% vs prior quarter ($39M vs $37M).
- Gross margin 32.4% (was 34.5% prior quarter).
- Operating margin expanded to -114.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $160M | $154M | $201M | $128M | — |
| Op margin | -348.5% | -188.7% | -154.8% | -237.6% | — |
| Net income | -$546M | -$310M | -$307M | -$314M | — |
| Gross margin | 28.6% | 24.2% | 26.3% | 38.2% | — |
| Gross profit | $45.8M | $37.3M | $52.8M | $49.0M | — |
| Operating income | -$558M | -$291M | -$310M | -$305M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · PacBio (PACB) Stock Gets Fair Value Boost After UBS Starts Coverage Neutral
2026-10-08 · Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
2026-10-08 · Pacific Biosciences of California Insider Sold Shares Worth $2,056,921, According to a Recent SEC Filing
2026-10-06 · PacBio Sinks 8% as TychoBio Endorses Its “Highest Quality Biological Data” – the Real Story Is More Complicated
2026-10-06 · Pacific Biosciences of California, TychoBio Collaborate to Generate Full-Length RNA Data for AI Model Training
2026-10-06 · PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
2026-10-06 · Why PacBio (PACB) Stock Is Trading Up Today
2026-10-02 · Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
2026-10-01 · 3 Biotech Stocks Put Traders Are Targeting Today
2026-09-30 · Why Is PacBio (PACB) Stock Soaring Today
2026-09-29 · Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex
2026-09-29 · Why PacBio (PACB) Stock Is Trading Up Today
Price (daily)
Full chart · RSI · MACD · patterns